+

US20020044988A1 - Nutritional composition and method for improving protein deposition - Google Patents

Nutritional composition and method for improving protein deposition Download PDF

Info

Publication number
US20020044988A1
US20020044988A1 US09/821,498 US82149801A US2002044988A1 US 20020044988 A1 US20020044988 A1 US 20020044988A1 US 82149801 A US82149801 A US 82149801A US 2002044988 A1 US2002044988 A1 US 2002044988A1
Authority
US
United States
Prior art keywords
composition
protein
source
vitamin
whey protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/821,498
Other languages
English (en)
Inventor
Eileen Fuchs
Clara Garcia-Rodenas
Yves Guigoz
Peter Leathwood
Kristel Reiffers-Magnani
Chandrasekhara Mallangi
Marco Turini
Helen Anantharaman
Bernard Beaufrere
Martial Dangin
Olivier Ballevre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nestec SA
Original Assignee
Nestec SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22851804&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20020044988(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nestec SA filed Critical Nestec SA
Priority to US09/821,498 priority Critical patent/US20020044988A1/en
Assigned to NESTEC S.A. reassignment NESTEC S.A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: REIFFERS-MAGNANI, KRISTEL, TURNI, MARCO, ANANTHARAMAN, HELEN GILLIAN, FUCHS, EILEEN C., MALLANGI, CHANDRASEKHARA R., BEAUFRERE, BERNARD, DANGIN, MARTIAL, GUIGOZ, YVES, LEATHWOOD, PETER, BALLEVRE, OLIVIER, GARCIA-RODENAS, CLARA L.
Publication of US20020044988A1 publication Critical patent/US20020044988A1/en
Priority to US11/077,464 priority patent/US20050153019A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/065—Microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L9/00—Puddings; Cream substitutes; Preparation or treatment thereof
    • A23L9/10—Puddings; Dry powder puddings
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to a composition for a nutritional supplement; a method of production of the composition; use of the composition in the manufacture of a functional food or medicament for the nutrition, methods for improving muscle protein synthesis, preventing muscle loss, and accelerating muscle mass recovery in patients recovering from illness or surgery, those with limited appetite such as the elderly, or anorexic patients, or those who have impaired ability to digest other sources of protein which comprises administering an effective amount of the composition.
  • Nutritional supplements are usually not intended to provide all the nutrients necessary for a nutritionally complete diet; instead they are generally intended to supplement the diet such that it becomes more nutritionally complete. However, in some instances they may provide complete nutrition.
  • Nutritional supplements which are based on other protein sources, such as whey protein, are also available or have been described in the literature.
  • the nutritional supplements based upon whey protein are provided in the form of fruit juices; for example as described in European patent application 0486425 and U.S. Pat. No. 5,641,531.
  • these products suffer from the problem that they generally do not provide a lipid source despite the fact that lipids are essential for adequate nutrition.
  • the invention provides a method for improving muscle synthesis comprising administering to an individual a therapeutically effective amount of a composition which comprises: (i) a protein source which provides at least about 8% and preferably at least about 10% total calories of the composition and which includes at least about 50% by weight of whey protein; (ii) a lipid source having an omega 3:6 fatty acid ratio of about 5:1 to about 10:1 and which provides at least about 18% of the total calories of the composition; (iii) a carbohydrate source which provides the remaining calories of the composition; and (iv) a balanced macronutrient profile comprising at least vitamin E and vitamin C.
  • a method of preventing muscle loss in an individual at risk of same includes administering a therapeutically effective amount of the above composition to the individual.
  • a method for accelerating muscle mass recovery in an individual includes administering a therapeutically effective amount of the above composition to the individual.
  • the invention provides a method of production of the composition which comprises blending the components in the required amounts.
  • composition for a nutritional supplement in accordance with the invention because it contains whey protein, can produce at least a 2-fold increase in whole body protein deposition in elderly people as compared to casein as the protein source. Therefore it may help such patients conserve muscle protein, rebuild muscle protein more rapidly, and hence get their strength back faster.
  • composition for a nutritional supplement in accordance with the invention because it contains whey protein, is easier to digest. Therefore the problem of a patient not consuming a sufficient amount of the supplement may be reduced. Similarly, the problem of a patient not consuming sufficient other foods may be reduced. Further, the composition has a well balanced lipid profile which provides a readily available energy source.
  • an embodiment of the composition includes whey protein as the primary source of protein (amino acids).
  • the whey protein can be sweet whey or acid whey or a combination thereof.
  • it is in the form of a whey protein partial hydrolysate produced by enzymatic treatment, preferably with trypsin, Alcalase or Novozyme, of whey protein and therefore is less viscous, lighter and provides the advantage that it is more easily digested than known compositions for fortified beverages and nutritional supplements.
  • the present invention is not limited to a whey protein hydrolysate.
  • a non-hydrolyzed whey protein can be used, preferably when the composition is made in a powder form.
  • the partial hydrolysis of whey protein with one or more of the above enzymes could be carried out at a pH ranging from about 6.6 to 8.8 (preferably about 8.5) and a temperature of about 40 to about 70 C (preferably about 65 C) at an enzyme concentration of about 0.5 to about 2.5 (preferably about 1.0) percent of the protein.
  • enzyme treatment is carried out for about 5 to about 120 minutes (preferably 15 minutes) to achieve adequate hydrolysis.
  • the whey protein hydrolysate represents a minimum of 50% of the protein content in the formulation. It is preferably the sole protein source but may be combined with intact whey protein or other protein or peptide sources including peptides naturally found in whey or milk such as caseino glycomacropeptide (CGMP).
  • CGMP caseino glycomacropeptide
  • At least about 50% by weight of the whey protein is hydrolyzed. Most preferably, at least about 70% by weight of the whey protein is hydrolyzed.
  • the protein source provides about 8% to about 20%, more preferably an embodiment for adults comprises a protein source which provides about 15% to about 18% (most preferably about 16%) of total energy of the composition.
  • a protein source which provides about 8% to about 14% (most preferably about 12%) of total energy of the composition.
  • the composition has a beneficial effect in persons requiring a nutritional supplement such as those suffering from muscle mass depletion and/or with limited appetite, such as those suffering or recovering from trauma, illness, or surgery, the elderly or those who have problems digesting other sources of protein such as persons having chronic gastritis who are known to have a reduced gastric pepsin digestion.
  • the composition enables such persons to retain or regain their strength quickly and therefore helps aid recovery of a convalescing patient.
  • the lipid source comprises about 40% to about 65% by weight of monounsaturated fatty acids; and about 15% to about 30% by weight of polyunsaturated fatty acids.
  • the saturated fatty acid content is preferably less than about 30% by weight.
  • Up to 20% by weight of medium chain triglycerides may be incorporated into the fat blend to facilitate digestion.
  • the lipid source may contain at least about 30 mg of vitamin E per 100 g of lipid source.
  • the lipid source provides about 25% to about 35% of total energy of the composition, more preferably about 30% of total energy of the composition.
  • the carbohydrate source comprises sucrose, corn syrup, maltodextrin or a combination thereof.
  • the carbohydrate source provides about 50% to about 60% of total energy of the composition.
  • an embodiment of the composition has a micronutrient composition having a unique profile rich in nutrients including one or more selected from the group which comprises Vitamin E, Vitamin C, taurine, folic acid and vitamin B-12.
  • the profile aids replenishment of nutrients required in higher quantities during periods of illness or recovery due to oxidative stress or inflammatory conditions and nutrients such as vitamin B-12 that may be poorly absorbed in those suffering from digestive disorders such as chronic gastritis or those who have undergone major intestinal surgery.
  • the micronutrients include at least folic acid and/or Vitamin B-12.
  • an embodiment of the composition comprises prebiotic fiber.
  • the fiber is selected from the group which comprises inulin, acacia gum, resistant starch, dextran, xylo-oligosaccharide (XOS), fructooligosaccharide (FOS), galactooligosaccharide, or a combination thereof.
  • an embodiment of the composition is in a powdered form for dilution with water before use or a ready to use fortified beverage in liquid form; or in the form of a pudding with a custard- or flan- like texture suitable for consumption by those with dysphagia or other swallowing problems; or in the form of a bar to provide an interesting selection of different varieties.
  • an embodiment of the composition is formulated for human consumption and/or administration.
  • an alternative embodiment is formulated for consumption by a companion animal.
  • an embodiment of the composition according to the present invention comprises the addition of at least one probiotic micro-organism.
  • the probiotic micro-organism provides the advantage of restoring the natural balance of the intestinal flora following antibiotic therapy.
  • an embodiment of the composition in powdered form contains a lactic acid bacterium and/or its fermentation metabolites.
  • the lactic acid bacterium is selected from the group which consists of L. johnsonii , Lb. Paracasei or a combination thereof.
  • This product has the advantage of inhibiting the growth of H. pylori in the stomach which is associated with the development of ulcer particularly in individuals having gastritis.
  • the probiotic bacteria comprises a Lb. Paracasei strain deposited under the number NCC 2461.
  • An advantage of the present invention is that it provides a composition that can be provided in a functional food product and which therefore does not require special administration.
  • Another advantage of the present invention is that, in the form of a pudding with a thin custard or flan like texture, the product can be consumed by those suffering from dysphagia.
  • a preferred embodiment is rich in Vitamin E and Vitamin C and as such can be used to replete levels of these nutrients in the blood following depletion related to infection, sepsis or other oxidative stress.
  • an embodiment additionally comprises taurine and as such can be used to replete levels of taurine in the blood following depletion related to infection, sepsis or other oxidative stress.
  • Another advantage of the present invention is that a preferred embodiment is particularly rich in Vitamin B-12 and folic acid which may be poorly absorbed in patients with gastric disease or following surgery to the intestinal tract.
  • FIG. 1 illustrates graphically, protein synthesis after consumption of nutritional supplements containing whey protein or casein.
  • FIG. 2 illustrates graphically, protein balance after consumption of nutritional supplements containing casein or whey protein.
  • This invention provides methods and nutritional supplements which are particularly suitable for providing supplemental nutrition to an individual requiring, or that could benefit from, increased muscle protein synthesis.
  • Such an individual may include the elderly. Due to its components the supplement is more rapidly digested and therefore the patient is more likely to consume a therapeutically effective amount of the supplement or other food to provide for adequate nutrition.
  • the protein source includes at least about 50% by weight of whey protein that preferably has been at least partially hydrolyzed.
  • the whey protein used to produce the hydrolysate may be a commercially available whey protein source; either based upon sweet whey or acid whey or a combination thereof.
  • the whey protein is a whey protein source containing more than 80% by weight of whey protein.
  • a suitable whey protein concentrate is LACPRODAN 9087 and suitable whey protein isolate sources include ALACEN 895 (New Zealand Milk Products Inc), BiPRO (Le Sueur Isolates of Le Sueur, Minn.), PROVON-190 (Avonmore Ingredients Inc of Monroe Wis.) and LACPRODAN 9212 (Royal Proteins, Inc of Rosemont Ill.).
  • the protein source may, if desired, include amounts of other suitable types of protein.
  • the protein source may further include minor amounts of casein protein, soy protein, rice protein, pea protein, carob protein, oat protein, milk protein, caseino-glyco-macropeptide or mixtures of these proteins.
  • the protein source may further include minor amounts of free amino acids.
  • the other suitable types of protein preferably comprise less than about 50% by weight of the protein source; more preferably less than about 30% by weight.
  • the protein source preferably provides about 8% to about 20% of the energy of the nutritional supplement.
  • the protein source may provide about 15% to about 18% of the energy of the nutritional supplement in an embodiment suitable for an adult or about 8% to about 14% of the energy of the supplement in an embodiment suitable for pediatric use.
  • the nutritional composition includes a lipid source.
  • the lipid source provides about 18% to about 40% of the energy of the nutritional supplement; more preferably 25% to about 35% of the energy of the nutritional supplement.
  • the lipid source may provide about 30% of the energy of the nutritional supplement.
  • the lipid source may include medium chain triglycerides (MCT) up to a level of 20% of the total lipid by weight.
  • MCT medium chain triglycerides
  • the lipid source is rich in monounsaturated fatty acids.
  • the lipid source contains at least about 40% by weight of monounsaturated fatty acids.
  • the lipid source contains about 45% to about 65% by weight of monounsaturated fatty acids; for example about 55% by weight.
  • the lipid source may also contain polyunsaturated fatty acids.
  • the lipid source contains about 15% to about 30% by weight of polyunsaturated fatty acids; for example about 20% by weight of polyunsaturated fatty acids.
  • the lipid profile of the supplement is preferably designed to have a polyunsaturated fatty acid omega-6 (n-6) to omega-3 (n-3) ratio of about 1:1 to about 10:1.
  • the n-6 to n-3 fatty acid ratio is about 5:1 to about 9:1; for example about 7:1.
  • the lipid source has a saturated fatty acid content of less than about 35% by weight; including medium chain triglycerides. More preferably, the lipid source contains less than about 30% by weight of saturated fatty acids.
  • Suitable lipid sources include high oleic sunflower oil, high oleic safflower oil, sunflower oil, safflower, rapeseed oil, soy oil, olive oil, canola oil, corn oil, peanut oil, rice bran oil, butter fat, hazelnut oil and structured lipids.
  • Fractionated coconut oils are a suitable source of medium chain triglycerides.
  • the nutritional supplement also includes a carbohydrate source.
  • the carbohydrate source preferably provides about 40% to about 65% of the energy of the nutritional supplement; especially about 50% to about 60% of the energy of the nutritional supplement.
  • the carbohydrate source may provide about 54% of the energy of the supplement.
  • carbohydrates may be used including maltodextrin, corn syrup, corn starch, modified starch, or sucrose, or fructose, or mixtures thereof. If desired, the supplement may be free from lactose.
  • the nutritional supplement preferably includes a complete vitamin and mineral profile.
  • sufficient vitamins and minerals may be provided to supply about 50% to about 500% of the recommended daily allowance of the vitamins and minerals per 1000 calories of the nutritional supplement.
  • the nutritional supplement preferably is rich in vitamin E.
  • the nutritional supplement may contain between 80 International Units and 120 International Units of Vitamin E per 1000 kcal. More preferably, the nutritional supplement contains about 30 International Units of Vitamin E per 250 ml serving of the supplement.
  • the nutritional supplement is also rich in Vitamin C providing between about 150 and about 250 mg per 1000 kcal or preferably about 60 mg per serving.
  • the supplement also preferably contains 200 g of folic acid and 3 g of Vitamin B-12 per serving.
  • Alternative embodiments of the supplement for pediatric use have a modified vitamin and mineral profile specifically tailored to the special needs of this age group.
  • the nutritional supplement further includes a source of a soluble, prebiotic fiber.
  • a prebiotic fiber is a fiber which beneficially affects the host by selectively stimulating growth and/or activity of bacteria in the colon which have the potential to improve host health.
  • Suitable soluble, prebiotic fibers include fructooligosaccharides (FOS) and inulin.
  • Suitable inulin extracts may be obtained from Orafti SA of Tirlemont 3300, Belgium under the trade mark “Raftiline”.
  • suitable fructooligosaccharides may be obtained from Orafti SA of Tirlemont 3300, Belgium under the trade mark “Raftilose”.
  • both FOS and inulin are provided in a ratio of about 60:about 40 to about 80:about 20, most preferably about 70:about 30.
  • Other possible fibers include gums such as guar gum, xanthan gum, xylo-oligosaccharides, gum arabic, pectin, acacia gum, resistant starch, dextrans or mixtures of these. The fiber selected should not induce satiety.
  • the soluble, prebiotic fibers are reported to promote the growth of bifidobacteria in the gastro-intestinal tract and, in certain circumstances prevent or decrease the growth of pathogens such as Clostridiae. Further, promoting the growth of bifidobacteria is reported to have various other beneficial effects. Also, during fermentation of the fibers in the colon, short chain fatty acids are produced. These fatty acids are a fuel for intestinal cells.
  • the soluble, prebiotic fibers are preferably present in an amount sufficient to provide about 4 to about 9 g of soluble, fermentable fiber to the patient per day. Therefore the prebiotic fibers may be present in an amount of about 6 g to about 12 g per 1000 kcal. Alternative embodiments comprise blends of prebiotic fibers in an amount of 9 g or less, for example 4 g of blend.
  • the nutritional supplement may also contain a source of insoluble dietary fiber.
  • Suitable sources of insoluble dietary fibers are hull fibers from legumes and grains; for example pea hull fiber, oat hull fiber, barley hull fiber, and soy hull fiber.
  • the nutritional supplement preferably has an energy content of about 800 kcal/l to about 2000 kcal/l; for example an energy content of about 1000 kcal/l or about 1500 kcal/l.
  • the nutritional supplement may be in the form of a soluble powder, a liquid concentrate, a pudding, a bar/snack or a ready-to-use formulation suitable for oral consumption or enteral administration. Ready to drink formulations are particularly preferred. Various flavors, sweeteners, and other additives may also be present. Artificial sweeteners such as acetosulfame and L-aspartyl based sweeteners may be used; for example acesulfame-K or aspartame or a mixture thereof.
  • the nutritional supplement may be produced, for example, by blending together the protein source, suspended in water, preferably water which has been subjected to reverse osmosis, and the lipid source.
  • Commercially available liquifiers may be used to form the liquid mixture
  • emulsifiers may be included in the blend.
  • the vitamins and minerals may be added at this point but are usually added later to avoid thermal degradation. Any added lipophilic vitamins, emulsifiers and the like may be dissolved into the lipid source prior to blending.
  • the liquid mixture is then homogenized; for example in two stages at about 7 MPa to about 40 MPa in the first stage and about 2 MPa to about 14 MPa in the second stage Protein hydrolysis is carried out as described earlier.
  • the whey protein may be reconstituted in water and hydrolyzed prior to the formation of an emulsion. This is the preferred procedure if a blend of hydrolyzed whey protein and other intact proteins are desired. If this is the practice adopted, then intact protein and lipid are added to the hydrolyzed whey protein following the hydrolysis procedure and the mixture is then homogenized. Termination of hydrolysis is achieved by denaturing the enzyme preferably by heat or by adjusting the pH or a combination thereof. Inactivation of the enzyme activity is accomplished by using conditions designed to minimize the detrimental effects of heat on the protein stability and product taste and quality. For example, enzyme inactivation may be achieved by heating to a temperature in the range of about 90° C. for 5 minutes to about 110° C. for about 15 seconds. This may be carried out by steam injection or by heat exchanger; for example a plate heat exchanger.
  • the liquid mixture may then be cooled gradually to about 20° C. to about 30° C.; for example by flash cooling and heat exchanger, preferably a plate heat exchanger.
  • the carbohydrate source may be added at this point or later either in a dry form or as a liquid slurry.
  • the mixture may then be further cooled to add any heat sensitive components; such as vitamins and minerals.
  • Water preferably water which has been subjected to reverse osmosis, may then be mixed in to form a liquid mixture.
  • the pH and solids content of the homogenized mixture is conveniently standardized at this point.
  • the liquid mixture may then be thermally treated for example using an aseptic process to reduce bacterial loads and sterilize the product.
  • the liquid mixture may be rapidly heated to a temperature in the range of about 110° C. for 5 minutes to about 150° C. for about 5 seconds. This may be carried out by steam injection or by heat exchanger; for example a plate heat exchanger.
  • the liquid mixture is then homogenized; for example in two stages at about 7 MPa to about 40 MPa in a first stage and about 2 MPa to about 14 MPa in a second stage.
  • the homogenized mixture is filled into suitable containers, such as cans.
  • suitable containers such as cans.
  • the filling may either be aseptic or the containers may be retorted.
  • Suitable apparatus for carrying out filling is commercially available.
  • whey proteins are able to stimulate postprandial protein synthesis in elderly people, while other proteins like casein are not.
  • a nutritional supplement according to an embodiment of the invention that contained whey protein produced a 2-fold increase in whole body protein synthesis in elderly people as compared to casein as the protein source. Therefore it may help to elderly people or patients suffering or recovering from illness, surgery or trauma to conserve muscle protein, rebuild muscle protein more rapidly, and hence get their strength back faster.
  • Whey protein is believed to be rapidly emptied from the stomach and readily hydrolyzed and absorbed in the intestine. This may result in a shorter post-prandial period in which the patient feels satiated and therefore may result in a rapid return of appetite. On the contrary, proteins like casein, which are slowly emptied from the stomach, provoke a steady, prolonged post-prandial period in which the patient may feel satiated. Therefore the nutritional supplement may be used to provide supplemental nutrition to elderly and sick and convalescing patients who are prone to anorexia and/or protein-energy malnutrition.
  • the nutritional supplement may be used as an indirect source of glutamine for animals or humans.
  • the nutritional supplement may be used to provide nutrition to stressed patients having a depleted glutamine status; for example for patients who are critically ill, or who are suffering from sepsis, injury, burns, inflammation, or patients recovering from surgery.
  • the nutritional supplement may be used to promote glutamine synthesis in patients suffering from injured or diseased intestines or to maintain the physiological functions of the intestine.
  • the nutritional supplement may be used to maintain or raise plasma glutamine levels in humans and animals and improve immune function.
  • the whey protein contains high levels of threonine, an important building block of mucins. Therefore the nutritional supplement has the advantage that it may be used to provide supplemental nutrition to patients suffering from, or at risk of, impaired or reduced mucin production; for example, patients undergoing an inflammatory response, suffering from malnutrition, suffering from cystic fibrosis, malignancy, chronic inflammatory bowel diseases, ulcerative colitis and Crohn's disease, undergoing treatment which includes the administration of non-steroidal anti-inflammatory drugs, and the like, and after total parenteral nutrition.
  • the whey protein contains high levels of cysteine, an important antioxidant and immediate precursor of glutathione. Therefore the nutritional supplement has the advantage that it can be used to provide supplemental nutrition to patients suffering from glutathione depletion and low antioxidant status.
  • the nutritional supplement may be used as a nutritional support for elderly or patients undergoing or recovering from acute or chronic inflammatory states.
  • the amount of the nutritional supplement required to be fed to a patient will vary depending upon factors such as the patient's condition, the patient's body weight, the age of the patient, and other sources of nutrition. However the required amount may be readily set by a medical practitioner.
  • the nutritional supplement may be taken in multiple doses, for example 2 to 5 times, to make up the required daily amount or may be taken in a single dose.
  • a ready-to-drink nutritional supplement is prepared.
  • the nutritional supplement includes the following components: Wet weight (% by weight of total Energy Component composition) (%) Protein 4.8 16 Whey protein Carbohydrate 13 54 Maltodextrin Sucrose Lipids 2.8 g 30 High oleic safflower oil Corn oil Canola oil Vitamins and Minerals At least 5% of RDA
  • the lipid mixture is made up of about 25% by weight of saturated fatty acids, about 55% by weight of monounsaturated fatty acids and about 20% by weight of polyunsaturated fatty acids.
  • the n-6:n-3 ratio is about 7:1.
  • the formula contains 30 IU of Vitamin E and 60 mg of Vitamin C per serving.
  • the energy density of the supplement is 1000 kcal/l.
  • a ready-to-drink nutritional supplement is prepared.
  • the nutritional supplement contains 16% of calories as protein of which 70% of the protein is hydrolyzed whey and the remainder is intact protein The remaining components are described in Example 1.
  • the energy density of the supplement is 1000 kcal/l.
  • a ready-to-drink nutritional supplement is prepared.
  • the nutritional supplement contains 16% of calories as protein of which 50% to 100% may be from whey or hydrolyzed whey protein.
  • the energy density of the supplement is 1500 kcal/l.
  • a powdered nutritional supplement is prepared.
  • the nutritional supplement contains 16% of calories as protein of which 50% to 100% may be whey or hydrolyzed whey protein.
  • the supplement may contain a probiotic bacteria, preferably L. johnsonii.
  • a ready-to-drink nutritional supplement is prepared that is tailored to the needs of growing children.
  • the nutritional supplement contains a lower percentage of calories as protein preferably 10-12% of calories as protein and a higher percentage of calories as carbohydrate.
  • the remaining components are as described in example 1.
  • the energy density of the supplement is 1000 kcal/l.
  • a powdered nutritional supplement is prepared.
  • the nutritional supplement contains 10-12% of calories as protein of which 50% to 100% may be whey or hydrolyzed whey protein.
  • the supplement may contain probiotics preferably B. bifidus and S. thermophilus
  • Alternate forms of the supplement are prepared such as puddings, flans and snack bar.
  • the pudding and flan forms are suitable for use by dysphagic subjects. All alternate forms are prepared to contain 10%-16% of calories as protein of which 50% to 100% may be whey or hydrolyzed whey.
  • L-[1- 13 C] leucine (99 mol percent excess, MPE), L-[5,5,5- 2 H 3 ] leucine (97 MPE) and sodium [ 13 C] bicarbonate (99 MPE) were obtained from Eurisotop (Gif-sur-Yvette, France). Isotopic and chemical purity of leucine were checked by gas chromatography-mass spectrometry (GCMS) and were tested for sterility and pyrogenicity before use.
  • GCMS gas chromatography-mass spectrometry
  • the tracers administered intravenously (L-[1- 13 C] leucine and [ 13 C] bicarbonate) were prepared in sterile pyrogen-free water. During each experiment, they were filtered through 0.22 ⁇ m membrane filters.
  • L-[5,5,5- 2 H 3 ] leucine was employed to produce two intrinsically labeled bovine milk proteins fractions: casein and whey proteins. Labeled proteins were obtained by infusing a lactating cow with the deuterated tracer, collecting the milk and purifying the 2 protein fractions by microfiltration and ultrafiltration techniques. The leucine enrichments were 8.28 and 8.16 MPE, respectively. Labeled proteins fractions were mixed with their respective unlabelled fraction, to obtain a total concentration of around 10 ⁇ mol/kg L-[5,5,5- 2 H 3 ] leucine. Protein purity and bacteriological quality met the criteria for human consumption.
  • a second catheter was inserted into a vein of the contralateral arm for tracer infusion.
  • a priming dose of [ 13 C] bicarbonate (6 mg)
  • a primed (4.2 ⁇ mol.kg ⁇ 1 ) continuous (0.06 ⁇ mol.kg ⁇ 1 .min ⁇ 1 ) infusion of L-[1- 13 C] leucine began and was continued for 590 min.
  • one of the supplements was ingested within 5 min.
  • Plasma [ 13 C] leucine and ketoisocaproate (KIC), and [ 2 H 3 ] leucine enrichments were measured by GCMS (Hewlett-Packard 5971A) using tertiary-butyldimethylsilyl derivatives. Corrections for the [ 13 C] and [ 2 H 3 ] enrichments were made. Leucine concentrations were measured by GCMS using norleucine as internal standard. [ 13 C] CO 2 enrichments were measured on a gas chromatography isotope ratio mass spectrometer ( ⁇ Gas system, Fisons Instruments, VG Isotech, Middlewich, England).
  • Total Leu Ra The rate of total leucine appearance into the peripheral circulation (Total Leu Ra) was calculated from the intravenous tracer (i.e. [ 13 C] leucine) infusion rate corrected for its time-dependent appearance into the plasma, from the leucinemia, and from the plasma leucine enrichment of the i.v. tracer.
  • Three different leucine fluxes constitute Total Leu Ra: i) the entry rate of exogenous (i.e. dietary) leucine (Exo Leu Ra), ii) the intravenously infused labeled leucine, and iii) the entry rate of endogenous leucine derived from protein breakdown (Endo Leu Ra).
  • Exo Leu Ra In postabsorptive conditions, Exo Leu Ra is zero, thus Endo Leu Ra equals Total Leu Ra corrected by the tracer infusion rate.
  • Exo Leu Ra was calculated from the simultaneous variation of the ingested tracer enrichment and of Total Leu Ra, according to Proietto's transposition of Steele's equations. In that situation, Endo Leu Ra was obtained by subtracting Exo Leu Ra and the tracer infusion rate from Total Leu Ra.
  • Splanchnic extraction which represents the fraction of ingested leucine taken up by the gut or liver during its first pass, was calculated as the difference between total leucine intakes minus the integrated area under the curve (AUC) of Exo Leu Ra rapported to total leucine intakes.
  • Total Leu Rd The total leucine rate of disappearance from plasma (Total Leu Rd) was calculated as Total Leu Ra minus the time-dependent changes in leucine pool size.
  • Total Leu Rd corresponds to the sum of the fluxes of leucine oxidized (Leu Ox) and utilized for protein synthesis (non oxidative leucine disposal or NOLD).
  • Leu Ox was obtained by dividing the [ 13 C] CO 2 production rate by the [ 13 C] KIC enrichment in plasma. NOLD was therefore Total Leu Rd minus Leu Ox.
  • Results were expressed as means ⁇ SD.
  • Statistical analysis were performed in order to i) characterize leucine kinetics modifications after supplement ingestion (i.e. changes from the postabsorptive state), and to ii) compare the 2 protocols. For that purpose, individual curves were standardized by subtracting the mean of the baseline values (time-points ⁇ 40 to 0) from each individual time-point.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pediatric Medicine (AREA)
  • Microbiology (AREA)
  • Animal Husbandry (AREA)
  • Birds (AREA)
  • Molecular Biology (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Feed For Specific Animals (AREA)
  • Fodder In General (AREA)
  • Grain Derivatives (AREA)
US09/821,498 2000-08-22 2001-03-29 Nutritional composition and method for improving protein deposition Abandoned US20020044988A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US09/821,498 US20020044988A1 (en) 2000-08-22 2001-03-29 Nutritional composition and method for improving protein deposition
US11/077,464 US20050153019A1 (en) 2000-08-22 2005-03-09 Nutritional composition and method for improving protein deposition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22711700P 2000-08-22 2000-08-22
US09/821,498 US20020044988A1 (en) 2000-08-22 2001-03-29 Nutritional composition and method for improving protein deposition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/077,464 Continuation US20050153019A1 (en) 2000-08-22 2005-03-09 Nutritional composition and method for improving protein deposition

Publications (1)

Publication Number Publication Date
US20020044988A1 true US20020044988A1 (en) 2002-04-18

Family

ID=22851804

Family Applications (4)

Application Number Title Priority Date Filing Date
US09/821,498 Abandoned US20020044988A1 (en) 2000-08-22 2001-03-29 Nutritional composition and method for improving protein deposition
US09/821,499 Expired - Fee Related US6592863B2 (en) 2000-08-22 2001-03-29 Nutritional composition
US10/437,347 Expired - Lifetime US6887850B2 (en) 2000-08-22 2003-05-13 Method to provide nutritional composition
US11/077,464 Abandoned US20050153019A1 (en) 2000-08-22 2005-03-09 Nutritional composition and method for improving protein deposition

Family Applications After (3)

Application Number Title Priority Date Filing Date
US09/821,499 Expired - Fee Related US6592863B2 (en) 2000-08-22 2001-03-29 Nutritional composition
US10/437,347 Expired - Lifetime US6887850B2 (en) 2000-08-22 2003-05-13 Method to provide nutritional composition
US11/077,464 Abandoned US20050153019A1 (en) 2000-08-22 2005-03-09 Nutritional composition and method for improving protein deposition

Country Status (15)

Country Link
US (4) US20020044988A1 (fr)
EP (2) EP1313376B1 (fr)
JP (2) JP2004506437A (fr)
CN (2) CN1267025C (fr)
AT (1) ATE313273T1 (fr)
AU (2) AU2001295488A1 (fr)
BR (2) BR0113367A (fr)
CA (2) CA2418285A1 (fr)
DE (2) DE60126104T2 (fr)
ES (2) ES2278781T3 (fr)
HU (2) HUP0301586A2 (fr)
MX (2) MXPA03001598A (fr)
PL (2) PL365934A1 (fr)
RU (2) RU2277355C2 (fr)
WO (2) WO2002015720A2 (fr)

Cited By (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030203042A1 (en) * 2002-04-24 2003-10-30 Cook Lisa Ann Compositions comprising milk protein concentrate and fatty acid and processes of their preparation
WO2003090560A1 (fr) * 2002-04-24 2003-11-06 The Procter & Gamble Company Compositions comprenant des proteines et des acides gras, et leurs procedes de preparation
WO2004002241A1 (fr) * 2002-07-01 2004-01-08 Unilever N.V. Composition induisant la satiete
US20040224036A1 (en) * 2003-05-09 2004-11-11 Bedding Peter M. J. Dietary supplement and method for the treatment and prevention of digestive tract ulcers in equines and other animals
US20050008679A1 (en) * 2003-05-09 2005-01-13 Bedding Peter M.J. Nutritional product and method for optimizing nutritional uptake in equine foals and other animals
US20050058671A1 (en) * 2003-05-09 2005-03-17 Bedding Peter M.J. Dietary supplement and method for treating digestive system-related disorders
US20050124576A1 (en) * 2003-12-05 2005-06-09 Hill's Pet Nutrition, Inc. Composition and method
US20050186306A1 (en) * 2004-02-19 2005-08-25 Susanne Sonneveld Low carbohydrate cereal-like food product
US6936598B2 (en) 2003-11-21 2005-08-30 Hill's Pet Nutrition, Inc. Composition and method
US20060110516A1 (en) * 2002-08-30 2006-05-25 Holtus Maria F Foaming ingredient and products containing the ingredient
US20060171992A1 (en) * 2002-12-20 2006-08-03 Gerhardt Cinderella C Blood glucose regulating composition
US20070031486A1 (en) * 2005-08-04 2007-02-08 Squashic Steven A Nutritional supplement for use under physiologically stressful conditions
US20070031487A1 (en) * 2005-08-04 2007-02-08 Squashic Steven A Nutritional supplement for women
US20070036837A1 (en) * 2003-05-09 2007-02-15 Bedding Peter M Dietary supplement and method for increasing the colostrum immunoglobulin levels in equine mares and other animals
US20070104700A1 (en) * 2003-06-23 2007-05-10 Garcia-Rodenas Clara L Nutritional formula for optimal gut barrier function
WO2007064225A1 (fr) * 2005-12-01 2007-06-07 Tine Ba Compositions comprenant des proteines et des lipides de lactoserum et procedes pour leur preparation
US20070166411A1 (en) * 2005-12-16 2007-07-19 Bristol-Myers Squibb Company Nutritional supplement containing long-chain polyunsaturated fatty acids
US20070172474A1 (en) * 2004-04-02 2007-07-26 University Of Tennessee Research Foundiation Dairy components effective for fat loss
US20080015166A1 (en) * 2004-06-22 2008-01-17 N.V. Nutricia Barrier Integrity in Hiv Patients
US20080064656A1 (en) * 2004-06-22 2008-03-13 N,V, Nutricia Improvement of intestinal barrier integrity
US20080171720A1 (en) * 2005-04-21 2008-07-17 N.V. Nutricia Nutritional Supplement For Hiv Patients
US20080207559A1 (en) * 1998-08-11 2008-08-28 N.V. Nutricia Carbohydrates mixture
US20080226746A1 (en) * 2005-08-04 2008-09-18 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US20090082249A1 (en) * 2005-04-21 2009-03-26 N.V. Nutricia Nutritional supplement for a category of hiv patients
US20090181128A1 (en) * 2008-01-10 2009-07-16 Better Bowls Consumable product
JP2009539883A (ja) * 2006-06-15 2009-11-19 マレー・ゴールバーン・コー−オペラティヴ・カンパニー・リミテッド 筋肉回復を高めるための乳清タンパク質および加水分解物を含む調製物
US20100069320A1 (en) * 2004-05-17 2010-03-18 N.V. Nutricia Synergism of gos and polyfructose
WO2010143939A1 (fr) * 2009-06-09 2010-12-16 N.V. Nutricia Nutrition destinée à améliorer la résistance musculaire des personnes âgées
US20110021417A1 (en) * 2003-09-19 2011-01-27 Rhoades Jonathan Robert Compositions comprising oligosaccharides
US20110077189A1 (en) * 2008-02-01 2011-03-31 N.V. Nutricia Composition for stimulating natural killer cell activity
EP2327315A1 (fr) * 2009-11-29 2011-06-01 Nestec S.A. Protocoles de dosage pour augmenter la synthèse des protéines chez un individu actif
US20110159055A1 (en) * 2005-08-04 2011-06-30 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US20110236500A1 (en) * 2005-04-21 2011-09-29 N.V. Nutricia Nutritional supplement with colostrum and epa or dha or gla
AU2011221852A1 (en) * 2010-03-04 2012-09-06 Megmilk Snow Brand Co., Ltd. Agent for preventing muscular atrophy
US20130078362A1 (en) * 2005-07-13 2013-03-28 Abbott Laboratories Liquid nutritional compositions containing unsaturated fatty acids
CN103648304A (zh) * 2011-04-22 2014-03-19 Mjn美国控股有限责任公司 基于强化乳的营养组合物
EP2380581A4 (fr) * 2008-12-24 2014-08-20 Megmilk Snow Brand Co Ltd Agent de développement musculaire
EP2822568A4 (fr) * 2012-03-09 2015-11-11 Fonterra Co Operative Group Utilisations de compositions à base de caséine
WO2016123512A1 (fr) * 2015-01-29 2016-08-04 Eric Weaver Procédé pour administrer des compositions d'igc afin de fournir des niveaux soutenu d'acides aminés
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity

Families Citing this family (155)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3142099A (en) * 1998-03-31 1999-10-18 Societe Des Produits Nestle S.A. Method for providing glutamine
US6833350B2 (en) * 2000-02-04 2004-12-21 Nestec S.A. Method for maintaining or improving the synthesis of mucins
DE50109557D1 (de) * 2000-06-28 2006-05-24 Sericausa B V Verwendung einer zubereitung aus oder mit einem gehalt an mindestens einem dissimilierten milchserum
US7214370B2 (en) 2000-12-18 2007-05-08 Probiohealth, Llc Prebiotic and preservative uses of oil-emulsified probiotic encapsulations
KR100419132B1 (ko) * 2000-12-29 2004-02-18 조성근 위·장 점막 부착성과 증식성, 내산성, 내담즙성 및헬리코박터 파일로리, 대장균 0157:ｈ7에 대한 항균성이우수한 락토바실러스 파라카제이 서브스패시즈 파라카제이ｃｓｋ 01
EP1243273A1 (fr) † 2001-03-22 2002-09-25 Societe Des Produits Nestle S.A. Composition contenant un agent prebiotique pour le traitement d'inflammation et d'activation anormal des agents immunitaires non-spécifiques
EP1281325A1 (fr) * 2001-07-30 2003-02-05 Societe Des Produits Nestle S.A. Composition nutritionnelle utilisée dans la prévention de la prolifération bactérienne
US20030134851A1 (en) * 2001-10-09 2003-07-17 Baxter Jeffrey H. Methods and compositions for providing glutamine
JP4338519B2 (ja) * 2001-10-19 2009-10-07 ビタ・パワー・リミテッド 食品サプリメントおよびそれを製造する方法
US20030099753A1 (en) * 2001-11-20 2003-05-29 Yang Baokang Juice based beverage compositions
ATE369045T1 (de) * 2001-11-26 2007-08-15 Nestec Sa Lagerstabiles nahrungsmittelprodukt enthaltend molkenprotein, verfahren zu seiner herstellung und verwendung
ATE492166T1 (de) * 2002-04-05 2011-01-15 Nestle Sa Zusammensetzungen und verfahren zur verbesserung von lipidassimilation in haustieren
JP2004168704A (ja) * 2002-11-20 2004-06-17 Otsuka Pharmaceut Co Ltd 筋肉増加用製剤
CN1984571A (zh) * 2003-01-07 2007-06-20 努特里奇亚有限公司 提高哺乳动物营养物利用的方法和其中使用的组合物
US7399496B2 (en) * 2003-02-07 2008-07-15 Glanbia Nutritionals (Ireland) Limited Hydrolyzed whey protein compositions
JP5177932B2 (ja) * 2003-03-03 2013-04-10 一般財団法人糧食研究会 腎炎の治療用や改善用の医薬組成物
US7951410B2 (en) * 2003-04-14 2011-05-31 Mead Johnson Nutrition Company Enteral compositions containing caseinoglycomacropeptide having an enhanced concentration of sialic acid
US7867541B2 (en) * 2003-04-14 2011-01-11 Mead Johnson Nutrition Company Compositions and methods of formulation for enteral formulas containing sialic acid
WO2004112512A1 (fr) 2003-06-23 2004-12-29 Nestec S.A. Supplementation en acides amines pour un microbiote sain de l'ecosysteme
WO2004112507A1 (fr) * 2003-06-23 2004-12-29 Nestec S.A. Preparation pour nourrissons et jeunes enfants
EP1638415B1 (fr) * 2003-06-23 2010-12-15 Nestec S.A. Formule infantile
RU2349312C2 (ru) * 2003-07-03 2009-03-20 Хилл`С Пет Ньютришн, Инк. Композиция и способ для ингибирования ухудшения умственных способностей у кошек
DK1641352T3 (da) * 2003-07-07 2010-12-06 Hills Pet Nutrition Inc Sammensætninger til forbedret oxidativ status hos katte
DE10331202A1 (de) 2003-07-10 2005-03-31 S.K. Enterprise Gmbh Verwendung von Molkenpermeat zur Behandlung des Metabolischen Syndroms
CN1298249C (zh) * 2003-08-05 2007-02-07 朱寿民 固态化全营养素液体食品及其制造方法
US7875291B1 (en) 2003-09-05 2011-01-25 Glu-Pro, Inc. Composition for managing diabetes, obesity, and hyperlipidemia and associated methods
US8871266B2 (en) * 2003-10-01 2014-10-28 Commonwealth Scientific & Industrial Research Organisation Probiotic storage and delivery
US8921422B2 (en) * 2003-10-01 2014-12-30 The Iams Company Methods and kits for enhancing ability to learn in a puppy or kitten
DE602004032579D1 (de) * 2003-11-25 2011-06-16 Virginia Tech Intell Prop Zusammensetzung für den tierischen verzehr sowie verfahren zur reduktion der map-kinaseaktivität
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
JP2007522208A (ja) * 2004-02-12 2007-08-09 キャンピナ・ネダーランド・ホールディング・ビー．ブイ． チオールのホメオスタシスを改良するためのシステインリッチのペプチド
DK1737304T3 (da) * 2004-04-09 2014-07-28 Nutricia Nv Flydende koncentreret formel
WO2006073430A2 (fr) * 2004-04-20 2006-07-13 The University Of Chicago Systeme d'administration therapeutique comprenant un compose de type peg de poids moleculaire eleve
US20060002985A1 (en) * 2004-07-02 2006-01-05 Zicker Steven C Compositions and methods for decreasing age-related deterioration in mental activities in companion animals
US20060019012A1 (en) * 2004-07-21 2006-01-26 Madonna Novotny Dysphagic dietary treatment
JP4488852B2 (ja) * 2004-09-17 2010-06-23 味の素ゼネラルフーヅ株式会社 体内脂肪低減作用を有する組成物
US20060088639A1 (en) * 2004-10-25 2006-04-27 Lewis Karen M Food additive, baked food composition and method for lowering blood cholesterol
DK1841332T4 (da) 2004-11-18 2013-05-06 Nutricia Nv Fortykningsmiddelsammensætning til dysfagipatienter
US20060134132A1 (en) * 2004-12-20 2006-06-22 Watkins Jackie M Protective barriers for micronutrients, phytochemicals, and nutraceuticals
US8252742B2 (en) 2004-12-30 2012-08-28 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
AU2005322887B2 (en) 2004-12-30 2010-03-11 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
EP2351492B1 (fr) * 2005-02-28 2014-08-20 N.V. Nutricia Composition diététique comprenant des probiotiques
US20060222682A1 (en) * 2005-03-18 2006-10-05 Andrews David A Nutraceutical Moringa composition
CA2601427C (fr) * 2005-04-06 2013-06-11 Novartis Ag Methode et composition pouvant ameliorer a des fins nutritionnelles la regulation de la glycemie et l'action de l'insuline
US20060247153A1 (en) * 2005-04-29 2006-11-02 Mcmahon Robert J Method of improving learning and memory in mammals
ES2607988T3 (es) 2005-05-31 2017-04-05 Iams Europe B.V. Bifidobacterias probióticas felinas
EP2270131A1 (fr) 2005-05-31 2011-01-05 The Iams Company Lactobacilles probiotiques félins
US20090209647A1 (en) * 2005-06-14 2009-08-20 Nestec S.A. Nutritional method
JP4464324B2 (ja) * 2005-06-29 2010-05-19 カルピス株式会社 発酵乳飲料の製造法
US8647689B2 (en) 2005-07-06 2014-02-11 Cargill, Incorporated Citrus fruit fibers in emulsions
US20070172542A1 (en) * 2005-07-18 2007-07-26 Next Proteins, Inc. Stimulant-containing nutrition bar product and method of manufacture
KR20080055903A (ko) * 2005-09-09 2008-06-19 머레이 걸번 코-어퍼러티브 컴퍼니 리미티드 우유 유래 조성물 및 근육량 또는 근력을 강화하기 위한용도
JP2009507045A (ja) * 2005-09-09 2009-02-19 マレー ゴールバーン コーオペラティブ コー リミテッド 筋肉炎症を減少させるための乳清生長因子抽出物の組成物
ES2334943T3 (es) * 2005-10-05 2010-03-17 Nestec S.A. Uso de una formulacion nutritiva para fomentar la recuperacion del crecimiento.
EP1940243B1 (fr) * 2005-10-24 2011-08-03 Nestec S.A. Preparation de fibres alimentaires et leur methode d'administration
EP2340725A1 (fr) * 2005-10-28 2011-07-06 Nestec S.A. Méthodes d'emploi d'acides aminés à chaîne ramifiée
ES2332149T3 (es) 2005-12-16 2010-01-27 N.V. Nutricia Composicion comprendiendo oligosacaridos en forma de fibras dieteticas solubles para su uso contra la atrofia muscular.
US8968721B2 (en) 2005-12-28 2015-03-03 Advanced Bionutrition Corporation Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
WO2007079147A2 (fr) 2005-12-28 2007-07-12 Advanced Bionutrition Corporation Véhicule de délivrance pour bactéries probiotiques, comprenant une matrice sèche en polysaccharides, saccharides et polyols sous forme de verre, et son procédé de préparation
CA2646672A1 (fr) * 2006-03-23 2007-09-27 Nestec S.A. Complements nutritionnels a haute teneur calorique
US7875303B2 (en) * 2006-03-31 2011-01-25 Kraft Foods Global Brands Llc Protein system and food products including same
US20070275150A1 (en) * 2006-05-26 2007-11-29 Ciell Michael P Nutritional composition and method of making the same
RU2306715C1 (ru) * 2006-07-27 2007-09-27 Андрей Андреевич Михайлов Сухая питательная смесь для диетологического питания
ES2310454B1 (es) * 2006-08-02 2009-10-15 Corporacion Alimentaria Peñasanta, S.A. Nueva composicion de fibra soluble, alimentos funcionales que comprenden dicha composicion y procedimiento para la preparacion de los mismos.
DE102006036285A1 (de) * 2006-08-03 2008-02-07 "S.U.K." Beteiligungs Gmbh Fraktionen aus Molkepermeat und deren Verwendung zur Prävention und Therapie des Typ-2 Diabetes und des Metabolischen Syndroms
US20090018186A1 (en) * 2006-09-06 2009-01-15 The Coca-Cola Company Stable beverage products comprising polyunsaturated fatty acid emulsions
US20080058418A1 (en) * 2006-09-06 2008-03-06 The Coca-Cola Company Stable polyunsaturated fatty acid emulsions and methods for inhibiting, suppressing, or reducing degradation of polyunsaturated fatty acids in an emulsion
US20100189767A1 (en) * 2006-09-19 2010-07-29 Eyal Shimoni Probiotic compositions and methods of making same
EP1911457A1 (fr) * 2006-10-12 2008-04-16 N.V. Nutricia Composition pour traiter ou prevenir l'infection gastrointestinale
EP2081449A2 (fr) * 2006-10-19 2009-07-29 Nestec S.A. Système d'alimentation à long terme pour personnes agées
CA2673120C (fr) 2006-12-18 2012-08-07 Advanced Bionutrition Corporation Produit alimentaire sec contenant un probiotique vivant
JP5799299B2 (ja) 2007-02-01 2015-10-21 ザ・アイムス・カンパニーＴｈｅ Ｉａｍｓ Ｃｏｍｐａｎｙ ブドウ糖代謝拮抗物質、アボカド又はアボカド抽出物を使用する、哺乳動物における炎症及びストレスの低下方法
FR2917949B1 (fr) * 2007-06-29 2009-10-30 Gervais Danone Sa Nouveau produit alimentaire fonctionnel comprenant un melange specifique de fibres
RU2348181C1 (ru) * 2007-07-12 2009-03-10 Андрей Андреевич Михайлов Сухая питательная смесь для диетологического питания (варианты)
HUP0700552A2 (en) * 2007-08-27 2009-03-30 Janos Dr Feher Method and composition inhibiting inflammation
BRPI0722045A2 (pt) * 2007-09-26 2014-03-25 Tibor Ficsur Produto complexo com eficácia de assimilação avançada para seres humanos e sua utilização
EP2818055B1 (fr) 2007-12-05 2020-10-28 N.V. Nutricia Composition nutritionnelle entérale liquide ayant une teneur énergétique élevée
WO2009113845A1 (fr) 2008-03-12 2009-09-17 N.V. Nutricia Composition nutritionnelle entérale liquide riche en protéine
EP2230946A4 (fr) 2007-12-11 2010-12-22 Cargill Inc Systèmes de mélange sec de fibres de pulpe d'agrume
US20090264520A1 (en) * 2008-04-21 2009-10-22 Asha Lipid Sciences, Inc. Lipid-containing compositions and methods of use thereof
EP2116140A1 (fr) * 2008-05-08 2009-11-11 Nestec S.A. Acide sialique pour le support du système immunitaire chez les personnes âgées
MX2010012171A (es) * 2008-05-21 2010-11-30 Stokely Van Camp Inc Bebida de recupercion a base de leche.
US9771199B2 (en) * 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
WO2009157759A1 (fr) * 2008-06-23 2009-12-30 N.V. Nutricia Composition nutritionnelle destinée à améliorer le système immunitaire des mammifères
WO2010002242A1 (fr) * 2008-07-02 2010-01-07 N.V. Nutricia Composition nutritionnelle pour améliorer la fonction musculaire et l'activité quotidienne
US9232813B2 (en) * 2008-07-07 2016-01-12 The Iams Company Probiotic supplement, process for making, and packaging
AU2009304238B2 (en) * 2008-10-17 2014-11-13 Société des Produits Nestlé S.A. Whey protein compositions, methods and uses
US20100178400A1 (en) * 2009-01-13 2010-07-15 Pepsico, Inc. Method of Preparing a Whole Grain Beverage
AU2009337091B2 (en) * 2009-01-15 2014-01-23 Société des Produits Nestlé S.A. Methods of diagnosing and treating dysphagia
US8936471B2 (en) 2009-02-15 2015-01-20 Cheryl L. Evans Flow rate measuring device
US9858831B2 (en) 2009-02-15 2018-01-02 Cheryl L. Evans Method for determining and prescribing quantifiable and customized diet for patient suffering from dysphagia
US8753124B2 (en) * 2009-02-15 2014-06-17 Cheryl Lynn Evans Method and apparatus for prescribing and preparing a reproducible and customized dysphagia diet
MX2011008608A (es) 2009-02-15 2011-09-09 Cargill Inc Sistemas de fibra de pulpa de citricos y sistemas de postre a base de gel.
US9623094B2 (en) 2009-03-27 2017-04-18 Advanced Bionutrition Corporation Microparticulated vaccines for the oral or nasal vaccination and boostering of animals including fish
ES2410376T3 (es) 2009-04-15 2013-07-01 N.V. Nutricia Nutrición antirreflujo para lactantes
DK2435554T3 (en) 2009-05-26 2017-10-30 Advanced Bionutrition Corp STABLE DRY POWDER COMPOSITION WITH BIOLOGICALLY ACTIVE MICRO-ORGANISMS AND / OR BIOACTIVE MATERIALS AND PROCEDURES FOR ITS PREPARATION
SG177664A1 (en) * 2009-07-20 2012-02-28 Nestec Sa Methods of attenuating the loss of functional status
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
EP2289527B1 (fr) * 2009-08-25 2018-02-21 Nestec S.A. Bifidobacterium longum et troubles IG fonctionnels
RU2428062C2 (ru) * 2009-10-09 2011-09-10 ЗАО "Академия-Т" Композиция для функционального напитка
PH12012500687A1 (en) * 2009-11-12 2012-10-29 Nestec Sa Nutritional composition for promoting gut microbiota balance and health
JP5177901B2 (ja) * 2009-12-02 2013-04-10 株式会社明治 栄養組成物
BR112012014660B1 (pt) * 2009-12-18 2018-02-06 Stokely-Van Camp, Inc. Bebida isotônicas e reidratantes e método para sua produção
US9504750B2 (en) 2010-01-28 2016-11-29 Advanced Bionutrition Corporation Stabilizing composition for biological materials
MX336076B (es) 2010-01-28 2016-01-07 Advanced Bionutrition Corp Composicion cristalina que seca que comprende un material bioactivo.
JP5695326B2 (ja) * 2010-02-12 2015-04-01 雪印メグミルク株式会社 タンパク質合成促進剤
US9050357B2 (en) * 2010-03-08 2015-06-09 Cp Kelco U.S., Inc. Compositions and methods for producing consumables for patients with dysphagia
WO2011109900A1 (fr) * 2010-03-10 2011-09-15 Inovobiologic, Inc. Aliment comprenant du glucomannane, de la gomme de xanthane et un alginate pour le traitement de troubles métaboliques
SG10201504748SA (en) * 2010-05-28 2015-07-30 Mjn Us Holdings Llc Nutritional compositions
JP6029257B2 (ja) * 2010-06-30 2016-11-24 森永製菓株式会社 筋肥大促進のための食品、補助食品、及びサプリメント
WO2012009426A1 (fr) * 2010-07-13 2012-01-19 Abbott Laboratories Préparation à haute tolérance pour nourrissons comprenant des protéines hydrolysées
AR082682A1 (es) 2010-08-13 2012-12-26 Advanced Bionutrition Corp Composicion estabilizadora de almacenamiento en seco para materiales biologicos
EP2444083A1 (fr) * 2010-10-21 2012-04-25 Nestec S.A. Cystéine et ingestion d'aliments
EP2452571A1 (fr) * 2010-11-15 2012-05-16 Nestec S.A. Analyse de compositions nutritionnelles complémentaires pour nourrissons et jeunes enfants
EP2452575A1 (fr) * 2010-11-15 2012-05-16 Nestec S.A. Analyse de formule nutritionnelle personnalisée en fonction de l'âge avec des probiotiques
US20120171328A1 (en) * 2011-01-05 2012-07-05 Dattatreya Banavara Composition comprising heat labile milk proteins and process for preparing same
CN103458891A (zh) 2011-04-13 2013-12-18 味之素株式会社 营养组合物
WO2013142482A1 (fr) 2012-03-20 2013-09-26 Particle Dynamics International, Llc Forme de dosage à base d'agent gélifiant
CN104244985A (zh) * 2012-03-23 2014-12-24 先进生物营养公司 生物材料的稳定化组合物
WO2013144268A1 (fr) * 2012-03-29 2013-10-03 Nestec S.A. Nutrition et exercice physique contre la malnutrition associée à la prise de médicaments chez les enfants
WO2014007606A1 (fr) * 2012-07-05 2014-01-09 N.V. Nutricia Produit pour l'utilisation dans le traitement prophylactique ou thérapeutique d'une émotion négative ou d'un comportement introverti
JP5763024B2 (ja) * 2012-09-07 2015-08-12 株式会社明治 栄養組成物
EP2956015B1 (fr) * 2013-02-15 2020-11-04 Société des Produits Nestlé S.A. Procédé pour la restauration et/ou le maintien de l'équilibre protéique net positif chez un enfant
WO2014134225A2 (fr) * 2013-02-26 2014-09-04 Pronutria, Inc. Polypeptides nutritifs, formulations et procédés pour traiter des maladies et améliorer la santé et l'entretien musculaire
US9820504B2 (en) 2013-03-08 2017-11-21 Axiom Foods, Inc. Rice protein supplement and methods of use thereof
MX2015011771A (es) 2013-03-08 2016-12-07 Axiom Foods Inc Suplemento de proteínas de arroz y métodos de uso de este.
US20150030674A1 (en) * 2013-07-29 2015-01-29 Corn Products Development, Inc. Composition for polyunsaturated fatty acids encapsulation and process of preparation
EP3076991A2 (fr) 2013-09-25 2016-10-12 Axcella Health Inc. Polypeptides nutritifs et leurs formulations, et procédés de production et d'utilisation associés
CN105992520A (zh) * 2013-12-19 2016-10-05 雅培公司 包含水解蛋白质的营养组合物
WO2015148384A1 (fr) 2014-03-26 2015-10-01 Abbott Laboratories Poudre de complément nutritionnel
PL3328215T3 (pl) 2015-07-29 2021-12-13 Advanced Bionutrition Corp. Stabilne suche kompozycje probiotyczne do specjalnych zastosowań dietetycznych
SG10201507786YA (en) * 2015-09-18 2017-04-27 Changi General Hospital Pte Ltd A food product and a method of preparing the same
GB2538335B (en) 2015-10-09 2017-05-24 Sis (Science In Sport) Ltd Compositions
CA3001078A1 (fr) 2015-11-17 2017-05-26 Nestec S.A. Compositions et procedes employant un polyphenol pour la sante musculosquelettique
US10744100B2 (en) 2015-11-17 2020-08-18 Societe Des Produits Nestle S.A. Compositions and methods using a polyphenol for musculoskeletal health
JP7300243B2 (ja) * 2015-12-03 2023-06-29 株式会社明治 栄養組成物
JP6924190B2 (ja) * 2015-12-18 2021-08-25 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 少なくとも１種のエンドペプチダーゼを用いる連続プロセスからの加水分解されたタンパク質を含む加熱滅菌された高タンパク質組成物
WO2017151540A1 (fr) 2016-02-29 2017-09-08 Abbott Laboratories Complément alimentaire en poudre
CN106616615A (zh) * 2016-12-23 2017-05-10 上海奥医生物医药科技有限公司 一种肿瘤专用型临床营养配方及其制备方法
CN106578093A (zh) * 2016-12-23 2017-04-26 上海奥医生物医药科技有限公司 一种创伤、感染、手术及其它应激状态专用型临床营养配方及其制备方法
JP6348193B1 (ja) * 2017-02-06 2018-06-27 日清食品ホールディングス株式会社 アミノ酸の由来判別方法
WO2018209131A1 (fr) 2017-05-12 2018-11-15 Axiom Foods, Inc. Produits de riz et systèmes et procédés de fabrication de ceux-ci
WO2018221526A1 (fr) * 2017-06-01 2018-12-06 株式会社明治 Composition nutritionnelle
CN107485019B (zh) * 2017-08-16 2021-01-12 东北农业大学 一种快速恢复体力并增肌的复合型健身粉
CN107752031A (zh) * 2017-10-26 2018-03-06 无限极（中国）有限公司 一种具有调节肠道菌群和保护胃粘膜功能的粉剂及其制备方法与应用
US11197917B2 (en) 2017-12-01 2021-12-14 ByHeart, Inc. Formulations for nutritional support in subjects in need thereof
CN108783437A (zh) * 2018-06-29 2018-11-13 山东探克生物科技股份有限公司 一种预消化的炎性肠病全营养配方食品及其制备工艺
US11058139B2 (en) * 2018-07-03 2021-07-13 Kerri Ann Langhorne Recovery supplement for horses
CN108991506A (zh) * 2018-07-18 2018-12-14 辰欣药业股份有限公司 一种不含纤维的预消化高能医用配方食品及其制备方法
CN109170466A (zh) * 2018-09-12 2019-01-11 广州亿喜生物科技有限公司 一种小麦草固体饮料及其制备方法
CA3116822A1 (fr) * 2018-12-13 2020-06-18 Societe Des Produits Nestle Sa Procedes pour ameliorer la sante metabolique chez un animal
EP3852354B1 (fr) * 2019-11-22 2023-10-25 Murata Manufacturing Co., Ltd. Dispositif de vibration, et unité d'imagerie comprenant ce dispositif de vibration
JP6753997B1 (ja) * 2019-12-17 2020-09-09 ユニ・チャーム株式会社 ペットの体重管理方法
CN111938144B (zh) * 2020-07-13 2021-09-24 浙江大学 一种半流体顺滑质构无渣全营养食品及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231085A (en) * 1988-10-31 1993-07-27 Sandoz Ltd. Compositions and methods for the enhancement of host defense mechanisms

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055446A (en) * 1988-10-21 1991-10-08 University Of Cincinnati Method to improve survival of patients during sepsis by diet composition
DE69103732T2 (de) 1990-11-01 1995-04-06 Sandoz Nutrition Ltd Hochsaures System enthaltende Nahrungsformulierungen.
JP2976349B2 (ja) * 1990-11-29 1999-11-10 雪印乳業株式会社 ｋ―カゼイングリコマクロペプチドの製造法
JP3183945B2 (ja) * 1992-04-02 2001-07-09 明治乳業株式会社 高フィッシャー比ペプチド混合物、その製造法、および肝疾患患者用栄養補給組成物
RU2045911C1 (ru) * 1992-11-18 1995-10-20 Московский институт прикладной биотехнологии Продукт для энтерального питания больных с высоким метаболическим стрессом "энергопластэн"
US5405637A (en) * 1993-06-30 1995-04-11 Bristol-Myers Squibb Company Milk protein partial hydrolysate and infant formula containing same
US5714472A (en) * 1993-12-23 1998-02-03 Nestec Ltd. Enternal formulation designed for optimized nutrient absorption and wound healing
US5567424A (en) * 1994-06-10 1996-10-22 Reliv International, Inc. Fiber, antioxidant, herbal and enzyme supplemented beverage composition for human consumption
CA2173780A1 (fr) * 1995-06-01 1996-12-02 Randy Grote Methode d'alimentation a l'aide de compositions sous diverses formes
US5728678A (en) * 1995-06-06 1998-03-17 Nestec Ltd. Method and composition for providing nutrition to a renal failure patient
US5641531A (en) 1995-09-28 1997-06-24 Abbott Laboratories Nutritional liquid supplement beverage and method of making same
DK0780055T3 (da) * 1995-10-27 2003-03-24 Nestle Sa Nærende kaffesammensætning
US5635199A (en) * 1995-10-27 1997-06-03 Nestec Ltd. Support of pediatric patients
US6077828A (en) * 1996-04-25 2000-06-20 Abbott Laboratories Method for the prevention and treatment of cachexia and anorexia
TW360501B (en) * 1996-06-27 1999-06-11 Nestle Sa Dietetically balanced milk product
IT1288119B1 (it) * 1996-06-28 1998-09-10 Renata Maria Anna Ve Cavaliere Composizioni dietetiche da utilizzare nell'alimentazione per via enterica
DE29724816U1 (de) * 1997-01-09 2004-07-22 Société des Produits Nestlé S.A. Probiotik enthaltendes Getreideprodukt
DE69837821T3 (de) * 1997-06-23 2015-05-28 Société des Produits Nestlé S.A. Zusammensetzung zur Ernährung von Diabetikern
EP0904784A1 (fr) * 1997-09-22 1999-03-31 N.V. Nutricia Préparation nutritionnelle probiotique
US5968586A (en) * 1997-10-09 1999-10-19 Wisconsin Alumni Research Foundation Production of κ-casein macropeptide for nutraceutical uses
DE59706697D1 (de) * 1997-12-19 2002-04-25 Merck Patent Gmbh Mehrschichttablette enthaltend probiotische Mikroorganismen wie z.B. Lactobacilli oder Bifidobakterien
US6200950B1 (en) * 1998-02-18 2001-03-13 Nestec S.A. Calorically dense nutritional composition
US5902743A (en) * 1998-03-20 1999-05-11 Wisconsin Alumni Research Foundation Probiotic bifidobacterium strain
ES2188259T3 (es) * 1998-10-16 2003-06-16 Nestle Sa Materia proteica de digestion relentizada y su utilizacion.
DE19860375A1 (de) * 1998-12-28 2000-07-06 Aventis Res & Tech Gmbh & Co Alpha Amylase-resistente Stärke zur Herstellung von Nahrungs- und Arzneimittel
ATE303077T1 (de) * 1999-04-29 2005-09-15 Nestle Sa Süssmolkeprotein enthaltende säuglingsnahrung

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231085A (en) * 1988-10-31 1993-07-27 Sandoz Ltd. Compositions and methods for the enhancement of host defense mechanisms

Cited By (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100016214A1 (en) * 1998-08-11 2010-01-21 N.V. Nutricia Carbohydrates mixture
US8277836B2 (en) 1998-08-11 2012-10-02 N.V. Nutricia Carbohydrates mixture
US9763466B2 (en) 1998-08-11 2017-09-19 N.V. Nutricia Carbohydrates mixture
US20080207559A1 (en) * 1998-08-11 2008-08-28 N.V. Nutricia Carbohydrates mixture
US8580295B2 (en) 1998-08-11 2013-11-12 N.V. Nutricia Carbohydrates mixture
WO2003090559A1 (fr) * 2002-04-24 2003-11-06 The Procter & Gamble Company Compositions comprenant un concentre de proteine de lait et un acide gras et procedes de preparation
WO2003090560A1 (fr) * 2002-04-24 2003-11-06 The Procter & Gamble Company Compositions comprenant des proteines et des acides gras, et leurs procedes de preparation
US20030203042A1 (en) * 2002-04-24 2003-10-30 Cook Lisa Ann Compositions comprising milk protein concentrate and fatty acid and processes of their preparation
WO2004002241A1 (fr) * 2002-07-01 2004-01-08 Unilever N.V. Composition induisant la satiete
AU2003242695B2 (en) * 2002-07-01 2007-12-06 Unilever Plc Satiety inducing composition
CN100352374C (zh) * 2002-07-01 2007-12-05 荷兰联合利华有限公司 引发过饱的组合物
US20050238694A1 (en) * 2002-07-01 2005-10-27 Gerhardt Cinderella C Satiety inducing composition
US7618648B2 (en) 2002-07-01 2009-11-17 Unilever Bestfoods, North America Division Of Conopco, Inc. Satiety inducing composition
US20060110516A1 (en) * 2002-08-30 2006-05-25 Holtus Maria F Foaming ingredient and products containing the ingredient
US20060171992A1 (en) * 2002-12-20 2006-08-03 Gerhardt Cinderella C Blood glucose regulating composition
US7988989B2 (en) 2003-05-09 2011-08-02 Freedom Health, Llc Nutritional product for enhancing growth and/or strengthening the immune system of equine foals
US20050008679A1 (en) * 2003-05-09 2005-01-13 Bedding Peter M.J. Nutritional product and method for optimizing nutritional uptake in equine foals and other animals
US20070036837A1 (en) * 2003-05-09 2007-02-15 Bedding Peter M Dietary supplement and method for increasing the colostrum immunoglobulin levels in equine mares and other animals
US7658964B2 (en) 2003-05-09 2010-02-09 Freedom Health, Llc Dietary supplement and method for increasing the colostrum immunoglobulin levels in equine mares
US20040224036A1 (en) * 2003-05-09 2004-11-11 Bedding Peter M. J. Dietary supplement and method for the treatment and prevention of digestive tract ulcers in equines and other animals
US20060008509A1 (en) * 2003-05-09 2006-01-12 Bedding Peter M J Dietary supplement and method for the treatment and prevention of digestive tract ulcers in equines and other animals
US20110045107A1 (en) * 2003-05-09 2011-02-24 Bedding Peter M J Dietary Supplement and Method for the Treatment of Digestive Tract Ulcers in Equines
WO2004100826A2 (fr) 2003-05-09 2004-11-25 Freedom Health, Llc Complement dietetique et technique de traitement et de prevention des ulceres presents dans le systeme digestif de chevaux et d'autres animaux
SG172480A1 (en) * 2003-05-09 2011-07-28 Freedom Health Llc Dietary supplement and method for the treatment and prevention of digestive tract ulcers in equines and other animals
US20100136044A1 (en) * 2003-05-09 2010-06-03 Bedding Peter M J Dietary Supplement and Method
US20050058671A1 (en) * 2003-05-09 2005-03-17 Bedding Peter M.J. Dietary supplement and method for treating digestive system-related disorders
US7824706B2 (en) * 2003-05-09 2010-11-02 Freedom Health, Llc Dietary supplement and method for the treatment of digestive tract ulcers in equines
EP1626706A4 (fr) * 2003-05-09 2008-07-23 Freedom Health Llc Complement dietetique et technique de traitement et de prevention des ulceres presents dans le systeme digestif de chevaux et d'autres animaux
US8197842B2 (en) 2003-05-09 2012-06-12 Freedom Health, Llc Dietary supplement and method
US7993669B2 (en) * 2003-05-09 2011-08-09 Freedom Health, Llc Dietary supplement and feed supplement for the treatment of digestive tract ulcers in horses
US8394370B2 (en) 2003-06-23 2013-03-12 Nestec S.A. Nutritional formula for optimal gut barrier function
US20070104700A1 (en) * 2003-06-23 2007-05-10 Garcia-Rodenas Clara L Nutritional formula for optimal gut barrier function
US20110021417A1 (en) * 2003-09-19 2011-01-27 Rhoades Jonathan Robert Compositions comprising oligosaccharides
US6936598B2 (en) 2003-11-21 2005-08-30 Hill's Pet Nutrition, Inc. Composition and method
US7754677B2 (en) 2003-12-05 2010-07-13 Hill's Pet Nutrition, Inc. Composition and method for reducing diarrhea in a mammal
US20050124576A1 (en) * 2003-12-05 2005-06-09 Hill's Pet Nutrition, Inc. Composition and method
US20050186306A1 (en) * 2004-02-19 2005-08-25 Susanne Sonneveld Low carbohydrate cereal-like food product
US20070172474A1 (en) * 2004-04-02 2007-07-26 University Of Tennessee Research Foundiation Dairy components effective for fat loss
US20100069320A1 (en) * 2004-05-17 2010-03-18 N.V. Nutricia Synergism of gos and polyfructose
US10426791B2 (en) 2004-05-17 2019-10-01 N.V. Nutricia Synergism of GOS and polyfructose
US9084433B2 (en) * 2004-06-06 2015-07-21 N. V. Nutricia Intestinal barrier integrity
US20160073669A1 (en) * 2004-06-06 2016-03-17 N.V. Nutricia Intestinal barrier integrity
US10499676B2 (en) * 2004-06-06 2019-12-10 N.V. Nutricia Intestinal barrier integrity
US20130053340A1 (en) * 2004-06-06 2013-02-28 N.V. Nutricia Intestinal barrier integrity
US20100167982A1 (en) * 2004-06-22 2010-07-01 N.V. Nutricia Barrier integrity in hiv patients
US20080015166A1 (en) * 2004-06-22 2008-01-17 N.V. Nutricia Barrier Integrity in Hiv Patients
US20080064656A1 (en) * 2004-06-22 2008-03-13 N,V, Nutricia Improvement of intestinal barrier integrity
US8252769B2 (en) * 2004-06-22 2012-08-28 N. V. Nutricia Intestinal barrier integrity
US11076623B2 (en) 2004-06-22 2021-08-03 N.V. Nutricia Intestinal barrier integrity
AU2005253898B2 (en) * 2004-06-22 2010-02-18 N. V. Nutricia Improvement of barrier integrity in hiv patients with fatty acids
US20080171720A1 (en) * 2005-04-21 2008-07-17 N.V. Nutricia Nutritional Supplement For Hiv Patients
US20110236500A1 (en) * 2005-04-21 2011-09-29 N.V. Nutricia Nutritional supplement with colostrum and epa or dha or gla
US20090082249A1 (en) * 2005-04-21 2009-03-26 N.V. Nutricia Nutritional supplement for a category of hiv patients
US9179702B2 (en) 2005-07-13 2015-11-10 Abbott Laboratories Liquid nutritional compositions containing unsaturated fatty acids
US20130078362A1 (en) * 2005-07-13 2013-03-28 Abbott Laboratories Liquid nutritional compositions containing unsaturated fatty acids
US8263137B2 (en) 2005-08-04 2012-09-11 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US7998500B2 (en) 2005-08-04 2011-08-16 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US8197854B2 (en) 2005-08-04 2012-06-12 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US20110151021A1 (en) * 2005-08-04 2011-06-23 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US8202546B2 (en) 2005-08-04 2012-06-19 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US20080226746A1 (en) * 2005-08-04 2008-09-18 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US20070031487A1 (en) * 2005-08-04 2007-02-08 Squashic Steven A Nutritional supplement for women
US20110159055A1 (en) * 2005-08-04 2011-06-30 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US8263667B2 (en) 2005-08-04 2012-09-11 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US7901710B2 (en) 2005-08-04 2011-03-08 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US20070031486A1 (en) * 2005-08-04 2007-02-08 Squashic Steven A Nutritional supplement for use under physiologically stressful conditions
WO2007064225A1 (fr) * 2005-12-01 2007-06-07 Tine Ba Compositions comprenant des proteines et des lipides de lactoserum et procedes pour leur preparation
RU2432086C2 (ru) * 2005-12-01 2011-10-27 Тине Ба Пищевая композиция, включающая сывороточные белки и липиды, способ ее получения и применение
US20070166411A1 (en) * 2005-12-16 2007-07-19 Bristol-Myers Squibb Company Nutritional supplement containing long-chain polyunsaturated fatty acids
JP2009539883A (ja) * 2006-06-15 2009-11-19 マレー・ゴールバーン・コー−オペラティヴ・カンパニー・リミテッド 筋肉回復を高めるための乳清タンパク質および加水分解物を含む調製物
US20090181128A1 (en) * 2008-01-10 2009-07-16 Better Bowls Consumable product
US20110077189A1 (en) * 2008-02-01 2011-03-31 N.V. Nutricia Composition for stimulating natural killer cell activity
EP2380581A4 (fr) * 2008-12-24 2014-08-20 Megmilk Snow Brand Co Ltd Agent de développement musculaire
AU2009332369B2 (en) * 2008-12-24 2016-06-02 Megmilk Snow Brand Co., Ltd. Muscle-building agent
EP2380581B1 (fr) 2008-12-24 2019-06-26 Megmilk Snow Brand Co., Ltd. Agent de développement musculaire
WO2010143939A1 (fr) * 2009-06-09 2010-12-16 N.V. Nutricia Nutrition destinée à améliorer la résistance musculaire des personnes âgées
EP2327315A1 (fr) * 2009-11-29 2011-06-01 Nestec S.A. Protocoles de dosage pour augmenter la synthèse des protéines chez un individu actif
WO2011064374A1 (fr) * 2009-11-29 2011-06-03 Nestec S.A. Protocoles de dosage destinés à augmenter la synthèse de protéines chez un individu actif
US20120329991A1 (en) * 2010-03-04 2012-12-27 Megmilk Snow Brand Co., Ltd. Agent for preventing muscle atrophy
AU2011221852A1 (en) * 2010-03-04 2012-09-06 Megmilk Snow Brand Co., Ltd. Agent for preventing muscular atrophy
AU2011221852B2 (en) * 2010-03-04 2016-06-30 Megmilk Snow Brand Co., Ltd. Agent for preventing muscular atrophy
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
CN103648304A (zh) * 2011-04-22 2014-03-19 Mjn美国控股有限责任公司 基于强化乳的营养组合物
EP2822568A4 (fr) * 2012-03-09 2015-11-11 Fonterra Co Operative Group Utilisations de compositions à base de caséine
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
WO2016123512A1 (fr) * 2015-01-29 2016-08-04 Eric Weaver Procédé pour administrer des compositions d'igc afin de fournir des niveaux soutenu d'acides aminés
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual

Also Published As

Publication number Publication date
RU2277354C2 (ru) 2006-06-10
ES2254496T3 (es) 2006-06-16
MXPA03001600A (es) 2003-06-04
AU2001291777A1 (en) 2002-03-04
HUP0301586A2 (hu) 2003-08-28
CA2418285A1 (fr) 2002-02-28
US20020044957A1 (en) 2002-04-18
EP1313378B1 (fr) 2007-01-17
JP2004506437A (ja) 2004-03-04
BR0113367A (pt) 2003-07-29
DE60126104D1 (de) 2007-03-08
DE60116112T2 (de) 2006-08-03
DE60126104T2 (de) 2007-11-15
WO2002015720A2 (fr) 2002-02-28
PL365934A1 (en) 2005-01-10
BR0113390A (pt) 2003-07-29
AU2001295488A1 (en) 2002-03-04
CN1469712A (zh) 2004-01-21
US20050153019A1 (en) 2005-07-14
EP1313376A2 (fr) 2003-05-28
EP1313376B1 (fr) 2005-12-21
WO2002015719A3 (fr) 2002-05-30
CA2419026C (fr) 2011-03-29
DE60116112D1 (de) 2006-01-26
CA2419026A1 (fr) 2002-02-28
PL365936A1 (en) 2005-01-24
WO2002015720A3 (fr) 2002-05-30
ATE313273T1 (de) 2006-01-15
HUP0301475A2 (hu) 2003-08-28
CN1267025C (zh) 2006-08-02
EP1313378A2 (fr) 2003-05-28
CN1471363A (zh) 2004-01-28
ES2278781T3 (es) 2007-08-16
US20030202992A1 (en) 2003-10-30
US6887850B2 (en) 2005-05-03
US6592863B2 (en) 2003-07-15
HUP0301475A3 (en) 2004-03-01
JP2004506436A (ja) 2004-03-04
WO2002015719A2 (fr) 2002-02-28
RU2277355C2 (ru) 2006-06-10
MXPA03001598A (es) 2004-11-01
CN1239096C (zh) 2006-02-01

Similar Documents

Publication Publication Date Title
CA2419026C (fr) Composition et procede nutritionnels permettant d'ameliorer le depot proteique
EP2348873B1 (fr) Procédé de production de compositions de protéines de lactosérum et produits susceptibles d'être obtenus de ceux-ci
US9884033B2 (en) Amino acid supplementation for a healthy microbiota ecosystem
JP2013216658A (ja) 術前及び／又は術後環境におけるプロバイオティックス
ZA200600601B (en) Infant or follow-on formula
EP2627196B1 (fr) Smoothie à base de produits laitiers pour stimuler la croissance chez des enfants

Legal Events

Date Code Title Description
AS Assignment

Owner name: NESTEC S.A., SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FUCHS, EILEEN C.;GARCIA-RODENAS, CLARA L.;GUIGOZ, YVES;AND OTHERS;REEL/FRAME:012117/0001;SIGNING DATES FROM 20010712 TO 20010729

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载